Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.59 |
| ▸ | MTOR | P42345 | 13/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.59 |
| ▸ | FLT3 | P36888 | 3/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1569074 | 0.83 | PIK3CA (0.60) | PIK3CAMTORPIK3CGFLT3PIK3R1 | |
| SCHEMBL1568845 | 0.82 | PIK3R1 (0.51) | PIK3CAMTORPIK3CGPIK3R1HDAC1 | |
| SCHEMBL1568883 | 0.82 | PIK3CA (0.65) | PIK3CAMTORPIK3CGFLT3PIK3R1 | |
| SCHEMBL1946711 | 0.82 | PIK3CA (0.56) | PIK3CAMTORPIK3CGFLT3PIK3R1 | |
| SCHEMBL8062689 | 0.81 | PIK3CA (0.64) | PIK3CAMTORPIK3CGFLT3PIK3R1 | |
| SCHEMBL1573338 | 0.81 | PIK3CA (0.55) | PIK3CAMTORPIK3CGFLT3PIK3R1 | |
| SCHEMBL1944921 | 0.80 | PIK3CA (0.58) | PIK3CAMTORPIK3CGPIK3R1HDAC1 | |
| SCHEMBL1569287 | 0.80 | PIK3CA (0.55) | PIK3CAMTORPIK3CGPIK3R1HDAC1 | |
| SCHEMBL4438219 | 0.80 | PIK3CA (0.76) | PIK3CAMTORPIK3CG | |
| SCHEMBL1569347 | 0.79 | PIK3CA (0.59) | PIK3CAMTORPIK3CGPIK3R1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513221-B2 | PI3K isoform selective inhibitors | Xcovery Holding, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513221-B2 | PI3K isoform selective inhibitors | Xcovery Holding, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513221-B2 | PI3K isoform selective inhibitors | Xcovery Holding, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY LLC | 2011-06-02 | — | — | US | disclosed |
| WO-2010005558-A2 | PI3K ISOFORM SELECTIVE INHIBITORS | XCOVERY, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | PI4KA, PIK3CA, PIKFYVE | PIK3CA 2/4885MTOR 147/4885PIK3CG 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.